mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar-Reference-Cited by-同舟云学术

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Published:2021-07-09 Issue:9 Volume:27 Page:1614-1621
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Chemaitelly Hiam^ORCID,Yassine Hadi M.^ORCID,Benslimane Fatiha M.,Al Khatib Hebah A.,Tang Patrick^ORCID,Hasan Mohammad R.^ORCID,Malek Joel A.^ORCID,Coyle Peter,Ayoub Houssein H.^ORCID,Al Kanaani Zaina,Al Kuwari Einas,Jeremijenko Andrew^ORCID,Kaleeckal Anvar Hassan,Latif Ali Nizar,Shaik Riyazuddin Mohammad,Abdul Rahim Hanan F.,Nasrallah Gheyath K.^ORCID,Al Kuwari Mohamed Ghaith,Al Romaihi Hamad Eid,Al-Thani Mohamed H.,Al Khal Abdullatif,Butt Adeel A.,Bertollini Roberto,Abu-Raddad Laith J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-021-01446-y.pdf

Reference36 articles.

1. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).

2. Tracking SARS-CoV-2 variants (World Health Organization, accessed 5 June 2021); https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

3. Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. https://pubmed.ncbi.nlm.nih.gov/33951357/ (2021).

4. Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233 (2021).

5. Qatar Monthly Statistics (Planning and Statistics Authority, accessed 26 May 2020); https://www.psa.gov.qa/en/pages/default.aspx

Cited by 339 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses;Human Vaccines & Immunotherapeutics;2024-09-09

2. Assessing Healthy Vaccinee Effect in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar;2024-07-29

3. Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19;New England Journal of Medicine;2024-07-18

4. Duration of effectiveness of the COVID-19 vaccine in Japan: a retrospective cohort study using large-scale population-based registry data;BMC Infectious Diseases;2024-06-28

5. SARS-CoV-2: pathogenesis, therapeutics, variants, and vaccines;Frontiers in Microbiology;2024-06-13